Table 1 Demographic and clinical data of both groups
Group I: RA patients (216) | Group II: SLE patients (104) | |
|---|---|---|
Age (years) mean ± SD | 45.5 ± 9.59 | 33.4 ± 7.9 |
Sex (M/F) | 81/135 | 15/89 |
Residence | ||
Urban/rural | 108/108 | 60/44 |
Marital status | ||
Married/not married | 207/9 | 94/10 |
Disease duration (months) Mean ± SD | 43.4 ± 25.6 | 52.1 ± 34.6 |
Disease presentation (number of patients) | ||
Articular | 216 | 60 |
Cutaneous | 0 | 98 |
Serositis | 4 | 56 |
Nephritis | 0 | 31 |
Neuropsychiatric | 0 | 4 |
Cardiac | 0 | 7 |
Hematological | 0 | 32 |
Vasculitis | 1 | 3 |
APS | 0 | 6 |
Comorbidities (number of patients) | ||
Hypertension | 13 | 10 |
Diabetes | 8 | 3 |
Hyperlipidemia | 6 | 4 |
Chronic kidney disease | 0 | 2 |
Interstitial lung disease | 2 | 1 |
Thyroid dysfunction | 6 | 8 |
HCQ shortage (Y/N) | 174/42 | 76/28 |
Duration of shortage (days) mean ± SD | 103.2 ± 49.4 | 88.6 ± 23.7 |
Lab findings N (%) | ||
RF | 147 (68%) | 5 (4.8%) |
Anti-CCP | 174 (80.5%) | 0 |
ANA | 12 (5.5%) | 104 (100%) |
Anti-dsDNA | 0 | 84 (80.8%) |
Hypocomplementemia | 0 | 46 (44.2%) |
Treatment received (number of patients) | ||
Methotrexate | 135 | 3 |
Leflunomide | 96 | 0 |
Azathioprine | 4 | 56 |
Mycophenolate mofetyl | 0 | 45 |
Cyclophosphamide | 0 | 4 |
Corticosteroids | 125 | 88 |
Biological therapy | 0 | 0 |